See the DrugPatentWatch profile for Nesina
What patent does “Nesina” refer to?
“Nesina” is the brand name for alogliptin, a DPP-4 inhibitor. Patent protection for Nesina therefore depends on which jurisdiction you mean and which specific alogliptin patent family you’re asking about (drug composition, formulation, method of treatment, or specific manufacturing/uses). The provided information here does not include any patent numbers, assignees, countries, or expiry dates, so I can’t identify the exact Nesina patent you’re referring to.
How can I find the exact Nesina (alogliptin) patent you need?
To answer accurately, you’d typically narrow the search by:
- Country or region (e.g., US, EU, Japan, India, Canada)
- Patent type (composition/formulation vs. method of use)
- Patent family or reference product (alogliptin vs. specific extended-release/formulation variants)
- Whether you want “first filing,” “grant,” or “expiry” (and whether you mean patent term extension)
If you share the country (or a patent number you’ve seen), I can translate that into the likely real-world protection scope and timing.
When does Nesina (alogliptin) patent protection typically expire?
Expiry varies by jurisdiction and by whether extensions apply (for example, supplementary protection certificates in parts of Europe). Without the specific patent (or jurisdiction), it’s not possible to give a correct expiry date.
Are there related patents beyond the main drug patent?
Yes. Even after a core composition patent expires, later patents can exist for things like:
- specific salt forms or polymorphs
- tablet formulations and coatings
- dosing regimens or particular patient subgroups
- manufacturing processes
Those can affect when generic or biosimilar-style competition can launch, depending on local patent “early entry” and litigation rules.
Are companies challenging Nesina patents or seeking generic entry?
Generic manufacturers often seek to enter once patents expire or challenge patent validity/scope through local regulatory pathways. The question again needs the jurisdiction and the specific patent(s) at issue to describe the litigation or dispute accurately.
---
What I need from you to answer precisely
Send one of the following and I’ll give a direct, sourced explanation:
1) The country (e.g., US or EU) plus what you want (expiry date, which patent, or what’s covered), or
2) A patent number / application number / link you’re looking at, or
3) The wording from the patent title (even partial), such as “alogliptin composition…”